Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Investigating the use of a novel Dualase (dual-endonuclease) system in repairing nonsense mutations and restoring CFTR expression in cystic fibrosis mouse and human airway models
EF 2022-23
Résumé
Cystic fibrosis (CF) is a monogenic disease that mainly affects the digestive system and lungs. Complications of the disease include thick mucus buildup in the lungs resulting in difficulty in breathing as well as malnutrition from nutrient absorption problems. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). These CF-causing mutations can be classified into seven categories, with only some conferring approved treatment. For instance, Trikafta is an approved treatment for patients with the common F508del mutation, but not in rare nonsense mutations like G542X and W1282X. Gene editing platforms have been studied in order to correct for these CFTR gene mutations, however many limitations still persist. DNA repair mechanisms that rely on the non-homologous end joining (NHEJ) pathway are only bounded by dividing cells and are not active in all cell types. Primer editors and base editors have also been shown to lead to off-target events.
As a result, there is a need for a DNA editor that is present in all cells and has high efficiency and accuracy. Dualase, a novel dual-endonuclease, has two active nuclease sites that cleaves the DNA of interest and leaves non-compatible ends to avoid the error-prone NHEJ DNA repair pathway. Dualase will be assessed in correcting the CF-causing mutations, F508del, G542X and W1282X, in patient-derived nasal cells and humanized mouse models. To this end, a deeper understanding into the therapeutic applications of the Dualase novel gene delivery platform will be achieved. This is important as gene therapy is the only permanent solution for CF as there is no evidence to suggest current modulators provide effective long-term protection without any serious side effects.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486584
Name
Antonio Krista
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the use of a novel Dualase (dual-endonuclease) system in repairing nonsense mutations and restoring CFTR expression in cystic fibrosis mouse and human airway models
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crispr-Cas9; Cystic Fibrosis; Dna Repair; Endonuclease; Gene Editing; Lung Disease; Mouse Model; Primary Nasal Cell; Therapeutic; Treatment
Abstract
Cystic fibrosis (CF) is a monogenic disease that mainly affects the digestive system and lungs. Complications of the disease include thick mucus buildup in the lungs resulting in difficulty in breathing as well as malnutrition from nutrient absorption problems. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). These CF-causing mutations can be classified into seven categories, with only some conferring approved treatment. For instance, Trikafta is an approved treatment for patients with the common F508del mutation, but not in rare nonsense mutations like G542X and W1282X. Gene editing platforms have been studied in order to correct for these CFTR gene mutations, however many limitations still persist. DNA repair mechanisms that rely on the non-homologous end joining (NHEJ) pathway are only bounded by dividing cells and are not active in all cell types. Primer editors and base editors have also been shown to lead to off-target events.
As a result, there is a need for a DNA editor that is present in all cells and has high efficiency and accuracy. Dualase, a novel dual-endonuclease, has two active nuclease sites that cleaves the DNA of interest and leaves non-compatible ends to avoid the error-prone NHEJ DNA repair pathway. Dualase will be assessed in correcting the CF-causing mutations, F508del, G542X and W1282X, in patient-derived nasal cells and humanized mouse models. To this end, a deeper understanding into the therapeutic applications of the Dualase novel gene delivery platform will be achieved. This is important as gene therapy is the only permanent solution for CF as there is no evidence to suggest current modulators provide effective long-term protection without any serious side effects.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Antonio, Krista
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~